Brentuximab + Lenalidomide for T-Cell Lymphoma
Trial Summary
What is the purpose of this trial?
This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma.
Research Team
John Reneau, MD,PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Eligibility Criteria
This trial is for adults with stage IB-IVB T-cell lymphoma that has returned or isn't responding to treatment. Eligible participants must have tried at least one standard chemotherapy, be in good organ function, and not have certain medical conditions like severe allergies to monoclonal antibodies or active infections. Women of childbearing potential must follow strict pregnancy prevention measures.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive brentuximab vedotin intravenously on day 1 and lenalidomide orally on days 1-21, repeating every 21 days for up to 16 courses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Brentuximab Vedotin
- Lenalidomide
Brentuximab Vedotin is already approved in United States, European Union for the following indications:
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Primary cutaneous anaplastic large cell lymphoma
- CD30-expressing mycosis fungoides
- Peripheral T-cell lymphoma
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Cutaneous T-cell lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
John Reneau
Lead Sponsor